See more : BEBO Health SA (MLBBO.PA) Income Statement Analysis – Financial Results
Complete financial analysis of SenesTech, Inc. (SNES) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SenesTech, Inc., a leading company in the Chemicals – Specialty industry within the Basic Materials sector.
You may be interested
- Lee Pharmaceuticals, Inc. (LPHM) Income Statement Analysis – Financial Results
- Tuktu Resources Ltd. (TUK.V) Income Statement Analysis – Financial Results
- LPI Capital Bhd (8621.KL) Income Statement Analysis – Financial Results
- PPG Industries, Inc. (0KEI.L) Income Statement Analysis – Financial Results
- PT Gaya Abadi Sempurna Tbk (SLIS.JK) Income Statement Analysis – Financial Results
SenesTech, Inc. (SNES)
About SenesTech, Inc.
SenesTech, Inc. develops a technology for managing animal pest populations through fertility control. It offers ContraPest, a liquid bait that limits reproduction of male and female rats. The company was incorporated in 2004 and is headquartered in Phoenix, Arizona.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.19M | 1.02M | 576.00K | 258.00K | 143.00K | 297.00K | 52.00K | 318.00K | 241.00K | 199.00K |
| Cost of Revenue | 654.00K | 555.00K | 356.00K | 281.00K | 101.00K | 241.00K | 45.00K | 196.00K | 0.00 | 0.00 |
| Gross Profit | 539.00K | 464.00K | 220.00K | -23.00K | 42.00K | 56.00K | 7.00K | 122.00K | 241.00K | 199.00K |
| Gross Profit Ratio | 45.18% | 45.53% | 38.19% | -8.91% | 29.37% | 18.86% | 13.46% | 38.36% | 100.00% | 100.00% |
| Research & Development | 1.23M | 1.86M | 1.95M | 1.49M | 1.91M | 2.40M | 3.19M | 2.71M | 7.22M | 3.20M |
| General & Administrative | 6.70M | 7.59M | 7.22M | 6.44M | 0.00 | 9.53M | 9.13M | 8.13M | 8.67M | 2.70M |
| Selling & Marketing | 317.00K | 631.00K | 584.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.02M | 8.28M | 7.22M | 6.44M | 8.42M | 9.53M | 9.13M | 8.13M | 8.67M | 2.70M |
| Other Expenses | 27.00K | -26.00K | -24.00K | -24.00K | 266.00K | 21.00K | 87.00K | -31.00K | -678.00K | 31.00K |
| Operating Expenses | 8.27M | 10.14M | 9.15M | 7.91M | 10.33M | 11.94M | 12.32M | 10.83M | 15.89M | 5.90M |
| Cost & Expenses | 8.93M | 10.69M | 9.51M | 8.19M | 10.43M | 12.18M | 12.37M | 10.83M | 15.89M | 5.90M |
| Interest Income | 26.00K | 7.00K | 4.00K | 3.00K | 45.00K | 25.00K | 29.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 4.00K | 2.00K | 11.00K | 28.00K | 42.00K | 74.00K | 86.00K | 87.00K | 855.00K | 632.00K |
| Depreciation & Amortization | 135.00K | 183.00K | 303.00K | 288.00K | 413.00K | 447.00K | 391.00K | 196.00K | 182.00K | 125.00K |
| EBITDA | -7.57M | -9.51M | -7.95M | -7.62M | -9.56M | -11.39M | -11.81M | -10.51M | -17.14M | -6.44M |
| EBITDA Ratio | -634.62% | -951.23% | -1,550.35% | -3,065.50% | -6,687.41% | -3,834.01% | -22,709.62% | -3,255.03% | -6,697.51% | -2,784.42% |
| Operating Income | -7.73M | -9.67M | -8.93M | -7.93M | -10.29M | -11.88M | -12.32M | -10.52M | -15.65M | -5.70M |
| Operating Income Ratio | -648.11% | -949.36% | -1,551.04% | -3,074.81% | -7,193.71% | -4,000.00% | -23,684.62% | -3,306.92% | -6,491.70% | -2,862.81% |
| Total Other Income/Expenses | 22.00K | -21.00K | 666.00K | -4.00K | 269.00K | -28.00K | 30.00K | -279.00K | -2.53M | -1.50M |
| Income Before Tax | -7.71M | -9.70M | -8.27M | -7.94M | -10.02M | -11.91M | -12.29M | -10.80M | -18.17M | -7.20M |
| Income Before Tax Ratio | -646.27% | -951.42% | -1,435.42% | -3,076.36% | -7,005.59% | -4,009.43% | -23,626.92% | -3,394.65% | -7,540.66% | -3,618.09% |
| Income Tax Expense | 0.00 | 19.00K | -292.00K | -239.00K | 308.00K | 46.00K | 173.00K | 56.00K | 177.00K | 663.00K |
| Net Income | -7.71M | -9.71M | -7.98M | -7.70M | -10.33M | -11.91M | -12.29M | -10.80M | -18.17M | -7.20M |
| Net Income Ratio | -646.27% | -953.29% | -1,384.72% | -2,983.72% | -7,220.98% | -4,009.43% | -23,626.92% | -3,394.65% | -7,540.66% | -3,618.09% |
| EPS | -11.51 | -186.39 | -171.04 | -614.56 | -1.90K | -245.50 | -450.00 | -672.84 | -1.09K | -403.93 |
| EPS Diluted | -115.10 | -186.39 | -171.04 | -614.56 | -1.90K | -245.50 | -450.00 | -672.84 | -1.09K | -403.93 |
| Weighted Avg Shares Out | 669.85K | 52.12K | 46.63K | 12.53K | 5.43K | 48.51K | 27.30K | 16.04K | 16.65K | 17.83K |
| Weighted Avg Shares Out (Dil) | 66.99K | 52.12K | 46.63K | 12.53K | 5.43K | 48.51K | 27.30K | 16.04K | 16.65K | 17.83K |
SenesTech, Inc. (SNES) Q3 2023 Earnings Call Transcript
SenesTech, Inc. (NASDAQ:SNES ) Q3 2023 Earnings Conference Call November 9, 2023 5:00 PM ET Company Participants Robert Blum - Lytham Partners, IR Joel Fruendt - Chief Executive Officer Tom Chesterman - Chief Financial Officer Conference Call Participants Operator Good...
SenesTech to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023
Financial results to be released after market close;Conference call to be conducted at 5:00 pm ET PHOENIX , Nov. 2, 2023 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES) will report financial results for its third quarter 2023, ended September 30, 2023,...
SenesTech Taking Orders for Evolve™ Soft Bait for Rodent Fertility Control
The first and only soft bait product featuring breakthrough, next generation technology that targets rodent populations by using nonlethal methods to restrict fertility. PHOENIX , Nov. 1, 2023 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES), the leader in fertility control to...
SenesTech Launches Evolve™ Soft Bait for Rodent Fertility Control
The first and only soft bait product featuring breakthrough, next generation technology that targets rodent populations by using nonlethal methods to restrict fertility. PHOENIX , Oct. 17, 2023 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES), the rodent fertility control experts and...
SenesTech to Participate in the Lytham Partners Fall 2023 Investor Conference
PHOENIX , Oct. 9, 2023 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES) today announced that Joel Fruendt, Chief Executive Officer, and Tom Chesterman, Chief Financial Officer, will present and host one-on-one meetings with investors at the Lytham Partners Fall 2023 Investor...
SenesTech Announces Closing of Warrant Exercise for $2.1 Million in Gross Proceeds
Isolate Bait System™ Now Shipping PHOENIX , Aug. 29, 2023 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), (www.senestech.com) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, announced today...
SenesTech, Inc. (SNES) Q2 2023 Earnings Call Transcript
SenesTech, Inc. (NASDAQ:SNES ) Q2 2023 Earnings Conference Call August 10, 2023 5:00 PM ET Company Participants Robert Blum - Lytham Partners Joel Fruendt - Chief Executive Officer Tom Chesterman - Chief Financial Officer Conference Call Participants Amit Dayal -...
SenesTech Announces Second Quarter 2023 Financial Results
July 2023 Sales Increased 126% as New Initiatives Take Hold Expanded Product Offerings Expected to Drive Future Growth PHOENIX , Aug. 10, 2023 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), (www.senestech.com) the rodent fertility control experts and...
SenesTech to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
Financial results to be released after market close; Conference call to be conducted at 5:00 pm ET PHOENIX , Aug. 3, 2023 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES) will report financial results for its second quarter 2023, ended June 30, 2023,...
SenesTech Launches Isolate Bait System™ for Contrapest®
Single step deployment system increases market potential while reducing install times by 80% Incorporates Enhanced ContraPest Formulation for Improved Performance in the Field PHOENIX , July 24, 2023 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), (www.senestech.com) the...
Source: https://incomestatements.info
Category: Stock Reports